Neuroscientist / 30 years experience developing pain medicines / CEO EptivA Therapeutics / Creating Personalized Analgesics® https://teapawt.net/t.co/PCtWbNkSyr
Joined April 2019
- Tweets551
- Following430
- Followers271
- Likes370
Pinned Tweet
Chronic #pain is an epidemic with 1 in 4 people suffering. #EptivA Therapeutics has developed the Pain Diseasome® and Pain Landscape® to enable the first precision medicine approach to pain creating more effective treatments and increasing clinical success.
#medicine #innovation
Mark J. Field PhD MSc retweeted
🚨Want to do a PhD? Check out BRC opportunities here: maudsleybrc.nihr.ac.uk/acade… if you want to do fMRI, Psychophysics and Pain research, then the one with me, Jan Hoffman and @bannister_lab is the one for you!
Mark J. Field PhD MSc retweeted
Vice-Chancellor Prof Irene Tracey has set out her vision for Oxford’s future as she is formally admitted as the University’s 273rd Vice-Chancellor, expressing her ambition ‘to be an advocate for Oxford like no other.’ 👏
Read more ➡ bit.ly/3W0SKUF
ALT Vice-Chancellor Prof Irene Tracey standing outside the Divinity School
ALT Inside the Sheldonian Theatre
ALT Vice-Chancellor Prof Irene Tracey delivering her Inaugural Address to the Sheldonian Theatre
ALT The Procession leaving the Sheldonian Theatre
An important article highlighting the tragic consequences of untreated #chronicpain. A complex and disturbing topic that needs to more prominent in the public eye. More funding into developing #nonopioid #analgesics is key to the long term solution
nytimes.com/2023/01/03/opini…
Interesting data showing that in this cohort study 40% of people in their 40's are suffering #chronicpain. Those suffering are likely to still be affected into their 50's and 60's highlighting the lack of effective treatments.
linkedin.com/posts/activity-…
Great to see this from @CCriadoPerez. Pain affects women more than men but research is mainly completed in males. Some conditions affect only women (endometriosis) & others are more prevalent in women (fibromyalgia). Research shows there are sex differences in pain mechanisms.
This quoted post is unavailable.
1
2
Exciting news for @EptivaTx as we become a clinical stage #biotech with this new licensing agreement for exclusive worldwide rights to a novel non-opioid Personalized Analgesics® asset. Find out more at our website here.
eptivatx.com/_files/ugd/5343…
1
The mechanisms & impact of chronic pain are extremely complex - as indicated in this image (Ref. and QR code on image) for chronic low back pain.
@eptivaTx is taking a #precisionmedicine approach to developing new #analgesics. See eptivaTx.com for more info.
1 in 4 people are suffering with chronic #pain and current treatments have limited efficacy with serious side effects and abuse potential. Find out more on how @eptivaTx are using Personalized Analgesics® research to create new safe precision medicines.
linkedin.com/posts/markfield…
ALT https://www.linkedin.com/posts/markfield10_pain-chronicpain-innovation-activity-6951107214174507008-pDqE?utm_source=linkedin_share&utm_medium=member_desktop_web
#Gabapentin was approved nearly 30 years ago& has become one of the most prescribed analgesics today, being widely used in 'off-label' pain conditions.
Developing safe, non-abuse potential new analgesics is a high priority for society.
jamanetwork.com/journals/jam…
Mark J. Field PhD MSc retweeted
Returning from a social media detox with a giveaway: 5 signed copies of The Painful Truth are up for grabs!
All you need to do is retweet this and follow me.
If you’ve already read it, do tag people who you think would enjoy it!
Mark J. Field PhD MSc retweeted
I have a PhD position available in my lab at the new @BrainBric. The project will investigate the use of virtual reality in chronic low back pain patients and is in collaboration with @KJWyles and @PatSchofield89. Apply here, deadline 22nd May:
jobs.ac.uk/job/CPD015/phd-st…
Mark J. Field PhD MSc retweeted
We're hiring! My lab at @BRIC is looking for a post doctoral researcher interested in functional MRI, pain psychophysics and immersive virtual reality. The project is funded by @acmedsci and is in collaboration with the excellent @mattos96 🥳 apply here: jobs.ac.uk/job/CPC082/post-d…
Restricting phase II patients in pain trials is causing huge attrition rates. #Aptinyx has just reported a failed DPN study lnkd.in/dhzcfVmM. The wrong patients for the NMDA mechanism.
There is an innovative way forward see thread for @EptivaTx precision medicine approach.
A #precisionmedicine approach is the way forward
Our Pain Landscape® research identifies that there are actually over 100 clinical conditions associated with neuropathic pain, but 85% of all clinical phase II studies are completed in just two conditions DPN and PHN (see graphic)
1
1
our research suggests over 60% of all neuropathic trails are in DPN. HOWEVER, it is a highly complex heterogeneous clinical group with patients suffering multiple types of neuropathies and various pain symptoms, which change over time.
We need true innovation in the way we develop new pain medicines
Our Personalized Analgesics® approach doesn't just take into account the target receptor, it utilises a novel network biology approach to map the protein-protein interactions following target engagement.
#innovation
1